CAMBRIDGE Mass. – July 24, 2024 – Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 (BIIB124) as a potential treatment in essential tremor (ET). The KINETIC 2 Study did not demonstrate a statistically significant dose-response relationship […]
Source: The Mayo Clinic A clinical trial is a research process to find new and better ways to understand, detect, control and treat health conditions. The scientific method is used to find answers to difficult health-related questions. Volunteers are an integral part of the research process. People with a particular disease as well as healthy […]
Praxis Precision Medicines has reported topline data from the Phase IIb Essential1 trial of ulixacaltamide (PRAX-944) to treat essential tremor (ET). The placebo-controlled, randomised, dose range finding, double-blind trial has been designed for assessing the safety, tolerability, and efficacy of once-a-day 60mg or 100mg ulixacaltamide treatment against a placebo after 56 days.
IRVINE, Calif., March 15, 2022 /PRNewswire/ — Allevion Therapeutics announced today that the Medical and Scientific Advisory Board (SAB) is expanding to include three new members — Rajesh Pahwa, M.D., Stuart H. Isaacson, M.D., and Patrick McCartney. The expansion of the board coincides with the successful completion of an initial pilot clinical study.
By Jean P. Hubble, M.D. The diagnosis is usually quite obvious – rhythmic shaking of the hands. Despite the fact that essential tremor (ET) is common and easily recognized, there are many aspects about the clinical presentation which are poorly understood. Virtually all individuals with ET have tremor of the hands. The next most frequently […]
Clinical trials can be confusing. Amber Trzeciak, with Cadent Therapeutics, explains how they work and why they are important for the development of new drugs and treatments for medical conditions like essential tremor.
BURLINGAME, Calif.–(BUSINESS WIRE)– Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, will present positive topline data from the landmark PROspective study for SymPtomatic relief of Essential tremor with Cala Therapy (PROSPECT) in a late-breaking poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders on September 25, 2019, in Nice, France. Cala Therapy, […]